This international forum, sponsored by the Nobel Foundation, focussed exclusively on cholinergic mechanisms and was inspired by the first meeting of its kind, organized by Professor Edith Heilbronn and her associates some 20 years ago. The Symposium `Cholinergic Neurotransmission: Functional and Clinical Aspects' took place on the Lidingo Island, Stockholm, in August 1989 and the resulting volume encompasses the contributions of a number of invited scientists prominent in the field of cholinergic neuroscience. The main objective was to provide a detailed overview of the cholinergic research-front of today with emphasis on the basic principles indicating the way to clinical applications. The chapters are organized in such a way as to guide the reader from molecular biology through basic cholinergic pharmacology into clinically oriented contributions that bear upon the number of diseases in which altered cholinergic function is pathophysiologically important, e.g. myasthenia gravis and myasthenic syndromes, disorders of movement and dementia as well as cholinergic mechanisms involved in the regulation of pain, mood and sleep.
This international forum, sponsored by the Nobel Foundation, focussed exclusively on cholinergic mechanisms and was inspired by the first meeting of its kind, organized by Professor Edith Heilbronn and her associates some 20 years ago. The Symposium `Cholinergic Neurotransmission: Functional and Clinical Aspects' took place on the Lidingo Island, Stockholm, in August 1989 and the resulting volume encompasses the contributions of a number of invited scientists prominent in the field of cholinergic neuroscience. The main objective was to provide a detailed overview of the cholinergic research-front of today with emphasis on the basic principles indicating the way to clinical applications. The chapters are organized in such a way as to guide the reader from molecular biology through basic cholinergic pharmacology into clinically oriented contributions that bear upon the number of diseases in which altered cholinergic function is pathophysiologically important, e.g. myasthenia gravis and myasthenic syndromes, disorders of movement and dementia as well as cholinergic mechanisms involved in the regulation of pain, mood and sleep.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Technology
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Illustrationen
Maße
ISBN-13
978-0-444-81148-6 (9780444811486)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Klassifikation
Content: I. Molecules and principles in cholinergic synaptology . 1. Molecular biology of choline acetyltranferase J. Mallet. 2. Structure and function of muscarinic receptors M.I. Schimerlik. 3. Multiple pathways for signal transduction through the muscarinic cholinergic receptor J.H. Brown, I. Trilivas, J. Trejo and E. Martinson. 4. Second-messenger responses associated with stimulation of neuronal muscarinic receptors expressed by a human neuroblastoma SH-SY5Y D.G. Lambert and S.R. Nahorski. 5. Function of nicotinic synapses D. Colquhoun, A.B. Cachelin, C.G. Marshall, A. Mathie and D.C. Ogden. 6. Expression and in vivo amplification of the human acetylcholinesterase and butyrylcholinesterase genes H. Soreq and H. Zakut. II. Cholinergic mechanisms in the peripheral nervous system. A. A neuromuscular transmission . 7. Spontaneous synaptic activity at developing neuromuscular junctions N. Tabti and M. Poo. 8. The basal lamina and stability of the mammalian neuromuscular junction C.R. Slater. 9. Functional morphology of the nerve terminal at the frog neuromuscular junction: recent insights using immunocytochemistry F. Torri Tarelli, F. Valtorta, A. Villa and J. Meldolesi. 10. Functional aspects on quantal and non-quantal release of acetylcholine at the neuromuscular junction S. Thesleff. 11. Mediatophore: a nerve terminal membrane protein supporting the final step of the acetylcholine release process M. Israel and N. Morel. 12. Cell surface ATP(P2y)-purinoceptors trigger and modulate multiple calcium fluxes in skeletal muscle cells J. Haggblad, H. Eriksson and E. Heilbronn. 13. Immunogenetic mechanisms in myasthenia gravis L. Steinman. 14. Newly recognized congenital myasthenic syndromes: I Congenital paucity of synaptic vesicles and reduced quantal release. II High-conductance fast-channel syndrome. III Abnormal acetylcholine receptor (AChR) interaction with acetylcholine. IV AChR deficiency and short channel open-time. A.G. Engel, T.J. Walls, A. Nagel and O. Uchitel. 15. Clinical pharmacokinetics of acetylcholinesterase inhibitors P. Hartvig, L. Wiklund, S.M. Aquilonius and B. Lindstrom. 16. Synaptic adaption in diseases of the neuromuscular junction P.C. Molenaar. 17. Current treatment of myasthenia gravis P.O. Osterman. 18. Current therapy of the Lambert-Eaton myathenic syndrome H. Lundh, O. Nilsson and I. Rosen. 19. Future prospects of cholinergic research on neuromuscular transmission S. Thesleff, E. Heilbronn, A.G. Engel and P.C. Molenaar. B. Autonomic nervous system . 20. Structural and functional aspects of acetylcholine peptide coexistence in the autonomic nervous system B. Lindh and T. Hokfelt. 21. The impact of muscarinic receptor subtypes on drug development H. Ladinsky. 22. Basic and clinical aspects on cholinergic agents in bladder dysfunction K.-E. Andersson and H. Hedlund. 23. Cholinergic regulation of the endocrine pancreas B. Ahren, S. Karlsson and S. Lindskog. 24.
